Discover OPKO Health's Q2 2025 earnings insights, highlighting asset sales, cost savings, and pipeline advancements.

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Arguably even more important is that UnitedHealth has been a dividend grower. Its total annual payout was recently $8.51 per share, up from $6.40 in 2022 and $3.45 in 2018. My colleague Keith Speights ...

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, ...

In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories.

Celcuity shares soar 186% after Phase 3 breast cancer trial shows triple therapy delays disease by over 7 months.